Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
1.59
% (maximum dilution rate)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Stock options (8th Series Stock Acquisition Rights)
Who receives how much
40,000 common shares (400 stock acquisition rights, 100 shares per right)
3 directors of the Company (share allocation breakdown: 非開示)
The lower thin line represents the existing number of shares to which these shares will be added.
No monetary payment is required in exchange for the stock acquisition rights.
Existing Shares and Increase
+1.59%Rate of increase
2,519,600 shares2,559,600Shares
Maximum 1.59% (if all of these stock acquisition rights are exercised)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The higher of the average closing price for the month preceding the month in which the allotment date falls and the closing price on the allotment date. The existence of an adjustment clause and any adjustment floor are Not disclosed.
Exercise period
19 June 2028 to 29 February 2036
Number of Stock Acquisition Rights
Total issued: 400; unexercised balance: Not disclosed
Categories and Number of Persons Covered
3 directors of the Company; allocation breakdown: Not disclosed (total: 40,000 shares)
Basis for determining the amount to be paid
The exercise price will be based on the average closing price of the Company's common shares in regular trading on the TSE on each trading day in the month preceding the month in which the allotment date falls, rounded up to the nearest yen. If this price is below the closing price on the allotment date, the closing price on the allotment date will apply. The specific closing prices, average share price, and discount or premium rate are Not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Stock options (8th Series Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | 40,000 common shares (400 stock acquisition rights, 100 shares per right) |
| Issue price and disposal price | No monetary payment is required in exchange for the stock acquisition rights. |
| Intended allottee | 3 directors of the Company (share allocation breakdown: Not disclosed) |
| Dilution Rate | Maximum 1.59% (if all of these stock acquisition rights are exercised) |
| Total number of issued shares | 2,519,600 shares (as of the end of May) → 2,559,600 shares (if all of these stock acquisition rights are exercised)（1.59％） |
| Basis for determining the amount to be paid | The exercise price will be based on the average closing price of the Company's common shares in regular trading on the TSE on each trading day in the month preceding the month in which the allotment date falls, rounded up to the nearest yen. If this price is below the closing price on the allotment date, the closing price on the allotment date will apply. The specific closing prices, average share price, and discount or premium rate are Not disclosed. |
| Exercise price | The higher of the average closing price for the month preceding the month in which the allotment date falls and the closing price on the allotment date. The existence of an adjustment clause and any adjustment floor are Not disclosed. |
| Exercise period | 19 June 2028 to 29 February 2036 |
| Number of Stock Acquisition Rights | Total issued: 400; unexercised balance: Not disclosed |
| Categories and Number of Persons Covered | 3 directors of the Company; allocation breakdown: Not disclosed (total: 40,000 shares) |
Items this document does not state (17)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company states that the scale of dilution resulting from the issuance of these stock acquisition rights is considered reasonable. No other specific reason for the issuance is provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.